Experimental cancer drug trial halted early

NCT ID NCT04982926

Terminated Disease control Sponsor: Taiho Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had specific genetic changes (EGFR or HER2). The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm glioblastoma HER2 positive breast carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER GLIOBLASTOMA NON-SMALL CELL LUNG CANCER SOLID TUMOR

Contacts and locations

Locations

CLCC Gustave Roussy

Villejuif, Cedex, 94805, France
Tennessee Oncology

Nashville, Tennessee, 37203, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.